Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

University of Oxford Spinouts 'Celleron Therapeutics' and 'Argonaut Therapeutics' will merge to form IngenOx Therapeutics. The new company will focus on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours.

Nick La Thangue, CEO of IngenOx, and Professor of Cancer Biology at the University of Oxford commented:

“We are very excited by the merger which creates a company with a highly innovative pipeline, a talented and driven management team supported by a balanced group of investor shareholders. This provides the basis for success and future growth. IngenOx has the critical mass to bring a range of novel cancer therapies through clinical development and onwards towards market launch. This is good news for patients, in our continued fight against cancers which remain clinically unmet.”

 Read the full story from Argonaut Therapeutics.

 

 

Similar Stories

OCION Funding Scheme: In conversation with David Church and Luciana Gneo

The mission of the Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is to pump-prime innovative Oxford-based immuno-oncology research and build capacity in cancer immunology. We sat down with 2023 awardees, David Church and Luciana Gneo, to discuss what research the fund will enable them to carry out.